
Gold-melting ATM becomes sensation in China as users cash in on soaring prices
The Gold ATM accepts items weighing over 3 grams and with at least 50% purity, including jewellery, coins, and bullion. PHOTO: GULF NEWS
Listen to article
A newly launched Gold ATM in a Shanghai shopping mall is drawing large crowds as residents rush to convert their old gold jewellery into instant cash amid soaring global gold prices.
According to Gulf New, the machine developed by Shenzhen-based Kinghood Group, the machine evaluates and melts gold items on-site, determining their purity and weight before transferring the equivalent cash—minus a small fee—directly into the user's bank account within 30 minutes. No paperwork is required.
The innovation has captivated the public, with demand surging so quickly that appointments are now fully booked through May, according to Chinatimes.com.
How it works?
The Gold ATM accepts items weighing over 3 grams and with at least 50% purity, including jewellery, coins, and bullion. Using advanced sensors and heating the gold to 1,200°C, the machine performs a real-time analysis. The final payout is based on live rates from the Shanghai Gold Exchange.
In a recent demonstration, a 40-gram necklace appraised at 785 yuan per gram resulted in a payout exceeding 36,000 yuan (approx. £4,000 or Dh18,200).
"The public's desire to cash out has significantly increased with the rising value of gold," said Xu Weixin of the Shanghai Gold Association. "This ATM offers a convenient and transparent alternative to traditional jewellers."
International attention spiked after Turkish tech influencer Tansu Yegen posted a video of the ATM in action, calling it 'simple, fast, and powerful.' Tech analyst Advait Arora added: 'That's how China does innovation.'
Social media reactions ranged from admiration to envy. 'Why can't we Americans have nice things like this?' one user asked. Another quipped, 'Perfect for India—but also a chain snatcher's delight.'
Despite some scepticism about the security and accuracy of purity verification, experts say the machine marks a significant step forward in automating personal asset management.
Kinghood Group has already rolled out similar machines across nearly 100 cities, with a second device planned for Shanghai. As economic uncertainty drives more people toward gold as a safe-haven asset, the demand for such machines is expected to grow.
'This is more than a machine—it's a shift in how people engage with their wealth,' said Arora. 'It blends ancient value with modern convenience.'
With its mix of speed, transparency, and tech-driven convenience, China's Gold ATM is reshaping how people access the value of their gold—bringing the future of finance into the mall.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Recorder
an hour ago
- Business Recorder
Military standoff with India: CM Murad thanks Turkiye for support
KARACHI: Syed Murad Ali Shah, Chief Minister of Sindh, thanked Turkiye for its support to Pakistan during its recent military standoff with India, he gave his remarks as a chief guest during annual Turkish Traditional Breakfast at Turkiye Consul General official residence. It was attended by Corp Commander Karachi Lt General Muhammad Avais Dastgir, Rear Admiral Abdul Munib, Rear Admiral Salman Ilyas, Mrs Gulsen Sangu Ms Zekiye Duru Sangu, Timurhan Abay Sangu, Ms Busra Akpolat Sertan Yuccer, Adem Abdullah Gunes, Muhammet Karatas, Murat Ozmen, Ahmet Murat Sekeralmaz, Ms Nazan Bulun, Ms Gulseven Goktas, Cem Malyemez, Sohail Tabba, actor Javed Shaikh, ADIG Javed Alam Adho, DIG, Maqsood Memon, Muhammad Atif Hanif, Chief Executive Officer Al Barka Bank, Abdullah Adem GUNES, Regional Director, Pak-Turk Maarif school and elite of town. Chief Minister, rejoiced the tradition, saying the annual event has introduced millions across the globe, including himself, to the palatable Turkish feasts. Host Consul General of the Republic of Turkiye Cemal Sangu, in his welcome speech said that we gather here to share not just a breakfast, but a tapestry of flavours, a testament to the warmth and generosity that binds and defines our culture of two Countries. Copyright Business Recorder, 2025


Business Recorder
7 hours ago
- Business Recorder
Syria flights to Turkey will start ‘soon': Erdogan
ISTANBUL: Turkish President Recep Tayyip Erdogan on Monday said flights by Syria's national carrier to Turkey would start 'soon'. 'Syrian Airlines will soon start flights to Turkey,' he said in a post on X, without saying when they would happen. He also said he hoped Turkey's AJet would 'hopefully be able to operate regular flights to Syria.' AJet is a budget subsidiary of Turkish Airlines, Turkey's national carrier, which itself began flights to Damascus in January, six weeks after the toppling of Syrian strongman Bashar al-Assad. Syrian Airlines – the country's flag carrier which was formerly known as SyrianAir – was hit by a barrage of Western sanctions imposed after the war began in 2011. Erdogan says may invite Syria's Assad to Turkiye 'at any moment' It was not immediately clear when the Syrian airline last operated a route to Turkey. Last month, Washington and Brussels lifted economic sanctions on Syria, allowing the government and private sector to reconnect with regional and international financial institutions after years of isolation. Authorities hope the move will pave the way for economic recovery in the war-torn country and help attract foreign investment, including in the energy sector. Still speaking about Syria, Erdogan pledged Turkey would announce 'good news regarding energy very soon' without giving further details. Last week, Syria signed a $7 billion energy deal with a consortium of Qatari, Turkish and US companies. The project, which includes four gas-powered plants in central and eastern Syria and a 1,000-megawatt solar farm in the south, aims to generate 5,000 megawatts.


Express Tribune
16 hours ago
- Express Tribune
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.